Neutralizing RNA aptamers
Nuclease-resistant RNA aptamers are provided which are capable of neutralizing PDGFRβ and are therefore useful in the diagnosis and/or therapy of PDGFRβ-associated and hyperproliferative-associated diseases, such as cancer and primary tumor metastasis. RNA aptamers provided herein include a modified synthetic RNA sequence wherein at least one pyrimidine residue is modified to 2′-fluoropyrimidine. Pharmaceutical compositions and diagnostic kits comprising RNA aptamers are also provided.
1. An RNA aptamer which comprises the nucleotide sequence 5′ UGUCGUGGGGCAUCGAGUAAAUGCAAUUCGACA 3′ (SEQ ID NO:1).
2. The RNA aptamer of claim 1 , which consists of the nucleotide sequence 5′ UGUCGUGGGGCAUCGAGUAAAUGCAAUUCGACA 3′ (SEQ ID NO:1).
3. The RNA aptamer of claim 1 , which consists of the nucleotide sequence GGGAGACAAGAAUAAACGCUCAAUCAUAAGAGGUAUCACAUUGUCGUGGGGC AUCGAGUAAAUGCAAUUCGACAGGAGGCUCACAACAGGC (SEQ ID NO:2).
4. The RNA aptamer of claim 1 , wherein said aptamer is nuclease-resistant.
5. The RNA aptamer of claim 1 , wherein at least one of the pyrimidine residues of the nucleotide sequence SEQ ID NO:1 or SEQ ID NO:2 is modified to 2′-fluoropyrimidine.
6. The RNA aptamer of claim 5 , wherein all of the pyrimidine residues are modified to 2′-fluoropyrimidine.
7. The RNA aptamer of claim 1 for use in a diagnostic and/or therapeutic method.
8. The RNA aptamer of claim 7 for use in the diagnosis and/or therapy of a hyperproliferative disease.
9. The RNA aptamer of claim 8 , wherein the hyperproliferative disease is selected from cancer and primary tumour metastasis.
10. The RNA aptamer of claim 9 , wherein the hyperproliferative disease is selected from the group consisting of: gastrointestinal cancer, prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-small cell lung cancer, cancer of the nervous system (i.e. glioma), kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer, bladder cancer and metastatic cancers of any of the foregoing.
11. A pharmaceutical composition comprising the RNA aptamer of claim 1 .
12. A kit for the diagnosis of a hyperproliferative disease comprising the RNA aptamer of claim 1 .